



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Alogliptin (Standard)

<b>Cat. No.:</b>	HY-A0023AR
<b>CAS No.:</b>	850649-61-5
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>21</sub> N <sub>5</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	339.39
<b>Target:</b>	Dipeptidyl Peptidase; Ferroptosis
<b>Pathway:</b>	Metabolic Enzyme/Protease; Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Alogliptin (Standard) is the analytical standard of Alogliptin. This product is intended for research and analytical applications. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC <sub>50</sub> of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin can be used for the research of type 2 diabetes <sup>[1][2][3]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : <10 nM (DPP-4) <sup>[1]</sup>

### REFERENCES

- [1]. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. *J Med Chem.* 2007 May 17;50(10):2297-300.
- [2]. Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. *Atherosclerosis.* 2010 Dec;213(2):429-35.
- [3]. Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. *Life Sci.* 2009 Jul 17;85(3-4):122-6.
- [4]. Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. *Eur J Pharmacol.* 2009 Jan 14;602(2-3):448-54.
- [5]. Hao FL, et al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. *Biomed Pharmacother.* 2019 Jan;109:181-187.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA